Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089) - Total Assets
Based on the latest financial reports, Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089) holds total assets worth CN¥1.67 Billion CNY (≈ $243.69 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Xinxiang Tuoxin Pharmaceutical Co.Ltd. book value and equity for net asset value and shareholders' equity analysis.
Xinxiang Tuoxin Pharmaceutical Co.Ltd. - Total Assets Trend (2019–2025)
This chart illustrates how Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s total assets have evolved over time, based on quarterly financial data.
Xinxiang Tuoxin Pharmaceutical Co.Ltd. - Asset Composition Analysis
Current Asset Composition (December 2025)
Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s total assets of CN¥1.67 Billion consist of 35.1% current assets and 64.9% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 8.4% |
| Accounts Receivable | CN¥58.59 Million | 3.5% |
| Inventory | CN¥181.61 Million | 10.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥80.12 Million | 4.8% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Xinxiang Tuoxin Pharmaceutical Co.Ltd. worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s current assets represent 35.1% of total assets in 2025, a decrease from 41.9% in 2019.
- Cash Position: Cash and equivalents constituted 8.4% of total assets in 2025, down from 14.0% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 9.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 10.9% of total assets.
Xinxiang Tuoxin Pharmaceutical Co.Ltd. Competitors by Total Assets
Key competitors of Xinxiang Tuoxin Pharmaceutical Co.Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Yabao Pharmaceutical Group Co Ltd
SHG:600351
|
China | CN¥3.34 Billion |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Sandoz Group AG
SW:SDZ
|
Switzerland | CHF21.61 Billion |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr67.43 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.22 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
Xinxiang Tuoxin Pharmaceutical Co.Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.01 | 4.10 | 3.38 |
| Quick Ratio | 2.76 | 3.01 | 2.53 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥438.98 Million | CN¥511.69 Million | CN¥558.32 Million |
Xinxiang Tuoxin Pharmaceutical Co.Ltd. - Advanced Valuation Insights
This section examines the relationship between Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.39 |
| Latest Market Cap to Assets Ratio | 0.30 |
| Asset Growth Rate (YoY) | -5.3% |
| Total Assets | CN¥1.67 Billion |
| Market Capitalization | $498.49 Million USD |
Valuation Analysis
Below Book Valuation: The market values Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s assets below their book value (0.30x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s assets decreased by 5.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Xinxiang Tuoxin Pharmaceutical Co.Ltd. (2019–2025)
The table below shows the annual total assets of Xinxiang Tuoxin Pharmaceutical Co.Ltd. from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.67 Billion ≈ $243.69 Million |
-5.29% |
| 2024-12-31 | CN¥1.76 Billion ≈ $257.29 Million |
-4.39% |
| 2023-12-31 | CN¥1.84 Billion ≈ $269.10 Million |
-0.23% |
| 2022-12-31 | CN¥1.84 Billion ≈ $269.73 Million |
+32.26% |
| 2021-12-31 | CN¥1.39 Billion ≈ $203.94 Million |
+47.25% |
| 2020-12-31 | CN¥946.48 Million ≈ $138.50 Million |
+27.93% |
| 2019-12-31 | CN¥739.85 Million ≈ $108.26 Million |
-- |
About Xinxiang Tuoxin Pharmaceutical Co.Ltd.
Tuoxin Pharmaceutical Group Co.,Ltd. engages in the research and development, production and sales of nucleoside (acid) APIs and pharmaceutical intermediates in China. It offers nucleoside (acid) products, such as pyrimidine series, purine series, and nucleotide series; nucleoside series, including citicoline sodium, ribavirin, inosine, acyclovir, azithromycin, cytosine, 5-fluorocytosine, cytidin… Read more